Core Viewpoint - Jincheng Pharmaceutical announced that its subsidiaries participated in the national centralized procurement for expiring drug agreements, with seven products, including Cefoperazone Sodium Injection and Ceftazidime Injection, expected to be selected for procurement [1] Group 1: Company Performance - The total sales revenue of the seven products expected to be selected for procurement in the first three quarters of 2025 is projected to be 414.46 million yuan, accounting for 21.45% of the company's total revenue during the same period [1] Group 2: Procurement Details - The procurement results are expected to be implemented by the end of March 2026, with the procurement cycle lasting until December 31, 2028 [1] - Medical institutions will prioritize the use of the selected drugs during the procurement cycle, ensuring the completion of the agreed procurement volume [1]

Core Viewpoint - Jincheng Pharmaceutical announced that its subsidiary, Guangdong Jincheng Jinsuo Pharmaceutical Co., Ltd., and its wholly-owned subsidiary, Shanghai Jincheng Suzhi Pharmaceutical Co., Ltd., participated in the bidding for the continuation procurement organized by the National Organization for the procurement of drugs whose agreements have expired [1] Group 1 - The company is involved in the bidding process for seven drug varieties, including Cefotaxime Sodium Injection and Ceftazidime Injection, as part of the national procurement program [1]